Coronavirus Update: US FDA Panel To Review J&J’s Vaccine On 26 February

Plus: Daiichi Signs Japan Deal With AZ

 
• By Scrip Team

Johnson & Johnson's vaccine produced a significantly lower efficacy readout than the mRNA frontrunners, but its success in preventing severe disease with one dose will be a gamechanger, if approved.  

J&J Covid vaccine
J&J's vaccine, named Ad26.COV2.S, could gain an emergency use authorization on 26 February.

More from COVID-19

More from Scrip